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longer an effective approach for best manufacturing practices. Increasing competition for new indications and
the launch of biosimilars for the monoclonal antibody market have put pressure on manufacturers to produce
at lower cost. Single-use technologies and continuous upstream processes have proven to be cost-efﬁcient op-
tions to increase biomass production but as of today the adoption has been only minimal for the puriﬁcation op-
erations, partly due to concerns related to cost and scale-up. This review summarizes how a single-use holistic
process and facility strategy can overcome scale limitations and enable cost-efﬁcient manufacturing to support
the growing demand for affordable biologics. Technologies enabling high productivity, right-sized, small foot-
print, continuous, and automated upstream and downstreamoperations are evaluated in order to propose a con-
cept for the ﬂexible facility of the future.
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1.1. Expensive Biologics
In the U.S. alone, biologics account for 40% of prescription drug spend-
ing, despite only 2% of the population using biologic drugs [1]. The cost of
thesemedications is quickly rising fromexpensive to simplyunaffordable.
This global issue will likely become more problematic with the steady
growth of theworld population and the advent of new biologic therapies.
Some strategic measures have been implemented to mediate the rising
prices such as a cost-effectiveness analysis methodology which appraises
health interventions and selects technologies based on the returns
expected for a ﬁnancial investment, therefore urging pharmaceutical
companies to provide biologics at competitive rates [2]. Many govern-
ments have passed legislature aimed at reducing expenditures on
follow-on biologics such as biosimilars [3] which decreases the costs of
a product entering the market by shortening the approval pathway, en-
suring compulsory licensing and encouraging data sharing. These strate-
gic initiatives are expected to moderate the high costs of new biologicsby encouraging a competitive market. Despite these strategic initiatives,
drug prices are reaching as high as $50,000 per treatment [4]. At the
same time, innovation manufacturers (bringing a new drug to market)
are battling low proﬁt margins. The average total cost of launching a
novel drug was $3 billion between 2004 and 2009, but the R&D portion
of that total rose from between 18% and 23% to 34%. Expenses exceeded
sales of novel drugs in this ﬁve year period [5].
1.2. Manufacturing Status Quo
Although monoclonal antibody (mAb) production has experienced
improvements from some single-use (SU) upstream and downstream
technologies, holistic strategies are required to combine and implement
these advances for more efﬁcient and economical production. Typical
mAbmanufacturing practices involve several stages of inoculum devel-
opment in small reactors followed by cell cultivation in larger stainless
steel bioreactors (5000 L to 25,000 L). The WAVE bioreactors, now of-
fered by GE Healthcare, were the ﬁrst SU bioreactors designed for
large scale manufacturing. Introduced in 1996, the WAVE bioreactor
consisted of a plastic bag on rocker platform that provides agitation
and gas transfer. Despite the evolution over the years, theWAVE biore-
actor is only available in volume sizes of up to 500 L and therefore usu-
ally operated as part of seed expansion inmammalian cell culture-based
bio-therapeutics manufacturing [6].
SU stirred tank bioreactors, such as GE Healthcare's Xcellerex biore-
actors thatwere introduced in themid- to late 2000s, are now common-
ly operated in small- to mid-scale bioprocessing projects [7]. In this
reactor, cells are cultured in a replaceable plastic bag that is housedf Computational and Structural Biotechnology. This is an open access article under the CC
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the bottom, center-mounted magnetic drive that couples with the
impeller in the bag [8].
Due toweight limitations, SU stirred tank bioreactors above 2000 L are
not feasible. However, over the last decade, there has been a dramatic
increase in expression yield from progress in cell lines, expression
systems, and culture [7]. These advances have made the large scale bio-
manufacturing with the Xcellerex bioreactors more practical. For
instance, 100 kg/year ofmAb can bemanufactured in a fewSU2000 L bio-
reactors operated continuously or in parallel, whereasmultiple ≥10,000 L
bioreactors were required for the same output only a decade ago.
Bioreactors have seen dramatic growth in the U.S. SU systems mar-
ket for cGMP (current good manufacturing practice) manufacturing,
and this increased adoption is expected to continue. In a 2014 survey
conducted by BioPlan Associates, 65.6% of clinical scale manufacturers
and 42% of commercial scale manufacturers have cited implementation
of SU bioreactors for new facilities as amajor factor that have resulted in
improvements in their bioprocessing [7]. According to the same report,
the SU upstream bioprocessingmarket is expected to grow by N320% in
ﬁve years. Following cell culture, primary recovery is performed by
centrifugation and ﬁltration from which the cell harvest is passed
along to low productivity downstream processes (DSPs) [9]. In large
manufacturing facilities, multiple bioreactors supply one ormore puriﬁ-
cation trains. These puriﬁcation trains have evolved to a common
platform over years, starting with Protein A afﬁnity chromatography
and followed by polishing steps (usually anion and cation exchange
chromatography and sometimes hydrophobic interaction chromatogra-
phy in place of cation exchange), and virus inactivation and ﬁltration
[10]. These long, complicated processes result in non-optimal yields
and increased risk of lost batches due to contamination or operator
error. Advances in cell culture technology have increased mAb titers,
but manufacturers cannot take advantage of high productivity bioreac-
tors until the puriﬁcation bottleneck has been mitigated.
Cost of goods (CoG) related to manufacturing has been identiﬁed as
one of the main cost-drivers of expensive biologics [11] with Protein A
resins being among the highest cost consumables in mAb processing
(up to €14,000/L) [12]. Traditional industrial mAb processes requiring
large volume unit operations, have high operating expenses (OpEx) in-
ﬂuenced by expensive chromatography resins and large buffer volumes.
Manufacturing facilities also necessitate high capital expenses (CapEx)
due to constructing cGMP facilities, stainless steel reactors, large
ﬁltration and chromatography skids, as well as associated piping and
hardware for the entire 20+ step process [9].
1.3. The Solution Resides in Innovation
Increased competition from biosimilars and other follow-on
biologics is forcing established manufacturers to ﬁnd or develop and
integrate new manufacturing technologies to stay competitive and
conserve their market share. The current manufacturing paradigm of
large scale cGMP manufacturing operations is no longer needed for the
majority of biologics produced today. Technology advancements in cell
culture operations and equipment, puriﬁcation media, techniques, and
hardware have simpliﬁed the large stainless steel operations into man-
ageable, small operations with disposable technology. A comparison of
data from typical processes from 1982 and 2004 show rises in stirred-
tank product titers from 50 mg/L to 4700 mg/L, with approximately 8×
improvement in speciﬁc productivity [13]. Sophisticated SU technologies
such as perfusion bioreactors are pushing productivities that are more
than 25× higher than batch culture [14] and emerging downstream
technologies, such as membrane chromatography, have demonstrated
potential to match the high bioreactor throughputs. Afﬁnity chromatog-
raphy is the puriﬁcation method of choice for antibodies because of the
highly speciﬁc binding between Protein A ligands and the Fc region of
immunoglobulins [15], but productivity is limited by the slow ﬂow
rates of resin columns. A novel membrane afﬁnity technology offershigh yield and N99% purity in a one-step puriﬁcation process with
much faster ﬂow rates than resin columns [16,17].Withmany improved
technologies emerging, the stage is now set for the industry to pragmat-
ically combine such technical innovations in bioprocessing to reduce the
costs of biotherapeutics.
In this paper, we present innovative concepts facilitated by modern
upstream and downstream processing technologies that enable
manufacturing of affordable biologics, with special emphasis on puriﬁ-
cation technologies. These novel strategies increase ﬂexibility and over-
all output, decrease manufacturing CoG, and reduce facility footprint.
The integrated facility design presented in this paper also enables local
manufacturing, further resolving problematic inventory and supply
chain issues faced by the pharmaceutical industry today.
2. Proposed Engineering Concept: Flexible Facilities of the Future
2.1. Industrial Production at Lab Scale to Reduce Costs and Increase
Flexibility
The current standard manufacturing scheme for biologics is opti-
mized for fed-batch bioreactors that are well adapted for suspension
cell culture processes, followed by a combination of different ﬁltration
and chromatography unit operations to achieve the target purity
requirement and yield. Both fed-batch bioreactors and resin column
chromatography operations experience an over-sizing problem when
scaled up to pilot and manufacturing process scales. Fed-batch reactors,
which comprise about 90% of commercial biologics production, require
large-volume tanks to counter the low productivity per unit volume
[18] and resin chromatography columns, limited by intrinsically slow
mass transfer rates, have to be over-sized in order to operate at a higher
ﬂow rate to achieve desirable productivity [19]. This approach of
attaining better productivity via enlarged working units occurs at the
expense of process economics and ﬂexibility. Large reactors (up to
25,000 L) and chromatography columns (up to 2 m in diameter with
10 cm to 20 cm bed height) directly increase the facility cost due to in-
creased building and equipment expenses as well as associated piping
and hardware costs (including preparing, holding, and cleaning) [20].
In addition to the economic disadvantage, over-sized bioprocess
plants offer limited ﬂexibility, which directly contradicts the emerging
trend in the biopharmaceutical industry of production on demand [21,
22]. In the case of low demand (for example, GSK reported Cervarix
sales were down 27% in Q1, 2015 [23]), process capacity will be greatly
wasted; therefore the unpredictability of demand necessitates facility
ﬂexibility. Moreover, the industry is transitioning from large, single-
product facilities to scalable, multi-product facilities for greater product
variety [24]. The emergence of personalized medicine and battleﬁeld
medicine as well as smaller product campaigns associated with orphan
drugs, biomarkers, and smaller disease paradigms puts more pressure
on manufacturing volume management [25–27]. Multi-product, small-
volume capabilities are unrealistic for over-sized bioprocess plants be-
cause of rigid infrastructure and non-disposable technologies. In these
situations, modiﬁcation of the facility to adapt to a more ﬂexible design
is tenable, but at a signiﬁcant cost and at a facility operation that is only
marginal in ﬂexibility.
Many advanced technologies have been explored to achieve full ca-
pacity utilization withmore ﬂexibility at less capital expenditure. By in-
tegrating state-of-the-art techniques and equipment in upstream and
downstream operations, manufacturing processes can be right-sized,
creating a smaller footprint which enables facilities to add or remove
unit operations depending on the demand without wasted capacity
and extra expenses. For example, Fig. 1 presents a concept developed
by Univercells and Natrix Separations for a biosimilar mAb. It is based
on standard puriﬁcation architecture but with emerging technologies
to enable a much simpler, quasi-continuous platform. The advantages
of this process can be pushed even further when improved process ar-
chitecture is incorporated, as demonstrated later.
Fig. 1. Univercells-Natrix automated, integrated, quasi-continuous mAb process concept. The continuous perfusion bioreactor and state-of-the-art DSP techniques are combined for
optimum productivity in a small, contained operation.
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For an upstream process using fed-batch cell culture, process scale-
up can be achieved by a faster cell culture production rate using multi-
ple bioreactors that are harvested at a certain frequency per week (“run
rate”), but this puts strain on the puriﬁcation process or requires larger
or dual column/ﬁltration operations to accommodate the biomass har-
vest frequency. A more common scale-up method to increase
manufacturing capability is via larger working vessels, which requires
developing a dedicated bioprocess facility through expansion or new
construction [28]. For example, for commercial scale mAb production,
the traditional fed-batch bioreactor usually cultures cells in 10,000–
25,000 L stainless steel tanks for 7–21 days with a product yield of 2–
6 g/L [18]. The renewed interest in perfusion bioreactors together with
cell culture advancements such as high titer mammalian cell lines,
transgenic expression, and microbial expression can signiﬁcantly im-
prove the upstream productivity per unit volume and reduce the re-
quirement of high-volume units [29]. Perfusion reactors utilize a
continuous supply of cell culture media while the growth-inhibiting
by-products are constantly removed over a prolonged production
phase (typically N20 days) to achieve 10–30 times higher cell density
compared to a fed-batch reactor [30]. Longer run duration and the abil-
ity to sustain biomass levels enable perfusion bioreactors to offer a pro-
ductivity advantage (in terms of mg/L/d) of at least 4-fold as compared
to a fed-batch unit with the same reactor volume [18]; therefore, the
same product quantity can be produced with less space and capital
cost. The continuous nature of a perfusion operation also makes it a
great candidate for continuous processing of biopharmaceutical pro-
teins. Implementation of perfusion reactors has been successfully com-
mercialized, ranging from large biopharmaceutical companies such as
Pﬁzer, Genentech, Shire, and Genzyme/Sanoﬁ [31–33] to small compa-
nies and innovative vaccine manufacturers such as CMC Biologics and
Crucell [34,35]. Although there are still drawbacks to the technology
such as usage of large volumes of medium, and high level of operator
training required due to the complexity and intensity of the operation,
the economic gain from smaller vessels and facilities has the critical im-
pact on process considerations [18,36].2.1.2. Right-sizing Downstream Processes
In downstream processing, clariﬁcation, capture, and polish steps
can be optimized by using high throughput, SU, and continuous tech-
nology. For clariﬁcation, centrifuges are not the right solution and arebecoming outdated because they are difﬁcult to scale and complicated
to operate [37]. Filtration is an alternative to centrifugation due to
much simpler implementation in ﬂexible, SU, continuous processes
andhas been demonstrated successfully for large scale, commercial pro-
cessing (Humira®), but the original designs in stainless steel housings
were complex at large scale. The new disposable ﬁltration designs
offer more ﬂexibility and scalability. For example, the Stax disposable
depth ﬁlter system (Pall) is a versatile, robust platform that can be oper-
ated in different modes depending on the process [38]. Millipore's
Clarisolve as well as D0HC and X0HC adsorptive depth ﬁlters can be
used for primary or secondary clariﬁcation directly from the bioreactor
or after low pH precipitation of impurities. By reducing host cell protein
(HCP) and DNA, these depth ﬁlters maximize loading on chromatogra-
phy columns while eliminating cell debris [39]. Filter aids like diatoma-
ceous earth can be added to cell culture ﬂuid to prevent blockages in
ﬁlters therefore allowing large batches to be clariﬁedwithmaximumef-
ﬁciency in SU formats as demonstrated by Sartoclear Dynamics (Sarto-
rius Stedim Biotech) [40]. These new modalities offer adaptability to
various process scales as well as contaminant reduction which
consequently helps to maximize the binding capacity of capture
chromatography.
Different chromatography techniques (afﬁnity, ion exchange, hy-
drophobic interaction) have been widely implemented in biologics pu-
riﬁcation in the format of resin columns. The majority of functional
ligands are grafted within internal pores of polymeric chromatography
resins. In order to interact with the ligands, molecules have to take
long and restricted diffusion pathways which signiﬁcantly hinder
mass transfer and limitﬂow rate [19]. In the attempt to increase produc-
tivity, resin columns are sized by volumetric ﬂow rate instead of capac-
ity, resulting in over-sized unit operations (up to 2 m in diameter with
10 cm to 20 cm bed height) that require vast investment in large col-
umns (especially for costly Protein A resins formAb capture), associated
hardware, supporting systems, and facilities. To be cost effective, these
large columns need to be amortized over many cycles and batches,
which increase the oversight of quality and regulatory groups for con-
sistent processing. Besides the economic issues, large columns can suf-
fer from scale-related packing problems including hysteresis, edge
effects, and resin compression [20]. Alternative formats for puriﬁcation
units including expanded bed adsorption, simulated moving beds, and
membrane chromatography are gaining popularity.
Expanded bed adsorption (EBA) is a potential cost-, time-, and
space-saving technology because it integrates solid–liquid separation
Fig. 2. Univercells' modular concept for combining USP and DSP in a small-footprint
cabinet. The output from the high-productivity perfusion bioreactor (in the left
chamber) is continuously feeding into the puriﬁcation train (in the right chamber). The
size and productivity of the perfusion bioreactor is matched with the downstream
recovery process for efﬁcient biologic manufacturing.
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centrifugation, chromatography capture) to one step. EBA can process
high cell density feeds directly from a bioreactor without risk of fouling
because the ﬂuidized bed increases the interstitial volume between ad-
sorbent particles therefore allowing cell components to ﬂow through
[41].While EBA offers obvious advantages such as reducing CapEx, buff-
er volumes, and operation time, there can be issues such as the need for
recirculation andnon-speciﬁc adsorptionwhich affects bed stability and
puriﬁcation performance [42]. New advancements to EBA such as the
second generation EBA Rhobust Technology provide an improved,
right-sized solution for mAb capture. Data presented at the BioProcess
International Conference and Exposition shows that in comparison to
a packed bed Protein A column, Rhobust MabDirect Protein A requires
one third of the processing time, half of the buffer usage, offers 12% bet-
ter yield, improves DNA clearance, and has comparable purity [43]. As
bioreactor cell density and productivity increase, EBA is a promising op-
tion that improves throughput and eliminates the need for large
ﬁltration areas required to deal with fouling from crude feeds.
Simulatedmovingbed (SMB) technology presents a fully continuous
method for performing chromatography. The BioSMB system built by
Tarpon Biosystems Inc. (now Pall) allows continuous loading of feed
as well as continuous elution as multiple Protein A columns are cycled
through the load, wash, and elution stages at different times [44]. The
Accelerated SeamlessAntibody Puriﬁcation (ASAP) process is a fully dis-
posable, continuous mAb DSP, based on AKTA periodic counter-current
chromatography (PCC), including Protein A, mixed mode, and anion
exchange resin columns where the three columns are cycled simulta-
neously [45]. Another advantage of SMB mode is that columns can be
connected in series so that any breakthrough from the ﬁrst column is
loaded onto the second column allowing the entire capacity of the
ﬁrst column to be usedwithout losing valuable product [46]. This allows
the use of columns with shorter bed heights that may have shallower
breakthrough curves, but can operate at faster residence times which
overall increases productivity [47]. Compared to batch resin chromatog-
raphy, SMB provides advantages including 30% high productivity, up to
40% increase in loading capacity, and up to 27% less buffer consumption
[46]. Executing chromatography steps in continuous SMB mode not
only decreases risk of contamination from human error and stoppages
in the process, but also decreases operation costs by reducing the
amount of resin, buffer, and time required for processing [48–51].
An alternative to resin columns is nanoﬁber adsorbents such as
Puridify's FibroSelect platform, which, although it has low binding capac-
ities (10 mg/mL), is able to ﬂow at very fast ﬂow rates (2400 cm/h) en-
abling high productivity as well as continuous processing [52].
Monolithic platforms would also be good for mAb puriﬁcation because
their high porosity structure provides effective mass transfer for the
antibody-sized targets and the ease of material preparation reduces
manufacturing costs, but monolith operation has yet to be translated
from analytical scales to industrial scales [53]. Monoliths are commercial-
ly available from several manufacturers including BIA Separations,
Millipore, and Sepragen [53].
Another alternative to resin chromatography is membranes which
have been gaining popularity for their ease of use and high throughput.
Unlike resin beads that heavily rely on diffusion,mass transport through
membranes is dominated by advection which allows much higher ﬂow
rates. Conventional ion exchangemembranes are available from several
suppliers including Pall (Mustang) and Sartorius (Sartobind), and these
arewell suited for ﬂow through (FT) applications. However, since the li-
gand density is lower than on resin beads, bind and elute (B&E) applica-
tions are limited [54]. Natrix's HD membrane technology contains a
high density of binding ligands in porous polymer hydrogels which al-
lows signiﬁcantly improved ﬂow characteristics without compromising
binding capacity. According tomAbprocess simulations, cycling smaller
devices with high binding capacity signiﬁcantly reduces CapEx because
required hardware is expensive for large columns, and decreases OpEx
due to the high cost of media (especially Protein A) [12]. Withthis new chromatography media, higher throughput can be achieved
without over-sizing the device and rapid cycling can be utilized to
reduce media volume, leading to increased productivity and ﬂexibility
at lower CapEx.
2.2. Integrated Facility Concept: Automated, Continuous, Small Footprint
Antibody Production
State-of-the-art technologies for upstream processes (USP) and DSP
described above can be integrated into a matched process, well-
balanced between the bioreactor output and the puriﬁcation through-
put. In theory, the entire process can be contained in a single, small
footprint cabinet, as shown in Fig. 2. The concept is based on standard
mAb puriﬁcation architecture where high throughput of USP and DSP
enables production in approximately 20 ft2 of the GMP suite, which
could be itself a modular clean room [35]. One cycle of the DSP, includ-
ing capture, virus inactivation, polishing, and sterile ﬁltration is
designed to be completed in only 24 h.
This strategy is depicted in Fig. 3, where a detailed process ﬂow dia-
gramderived from Fig. 1 shows the operation parameters (extrapolated
from lab scale proof of concept) of daily production and puriﬁcation. For
this hypothetical process, a 100 L high density perfusion bioreactor can
achieve higher product output compared to the traditional fed-batch
cell culture technique. Operating at 2 volumes per day with a titer of
2.5 g/L, the perfusion bioreactor can produce up to 5 kg of mAb over
10 days (approximately 120 kg annually over 24 perfusion runs). A
novel, SU perfusion reactor in development by Univercells has the po-
tential to realize this high efﬁciency production [55,56]. In contrast, pro-
ducing 100 kg of mAb annually using fed-batch bioreactors typically
requires 15 batch runs with a titer of 5 g/L in reactors 20× larger [57].
Hydrogel membranes that are appropriately sized for large-scale
mAb puriﬁcation are a cost efﬁcient solution for keeping up with high
culture productivity as shown in Fig. 3 (data shown for eachmembrane
column is extrapolated from N3 independent lab scale experiments). A
prototype Protein A afﬁnity membrane column has demonstrated
45 g/L binding capacity with 6 s residence time while still achieving
over 95% recovery. A 0.5 L membrane column would be cycled 20
Fig. 3. Rapidmulti-cycling enables small-footprint DSP tomatch the throughput of high-productivity USP. The conceptual process projected from lab scale proof of concept demonstrates a
puriﬁcation train that is capable of keeping pacewith the perfusion bioreactor output. The process ismade up ofNatrixmembrane columns (Protein A, HD-Sb (CEX) andHD-Q (AEX)) that
are sized just right for productivity, economy, and ﬂexibility.
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comparison, amuch larger 24 L resin columnwould take 5 cycles to pro-
cess the same batch in a similar time frame. This example shows how
right-sizing promotes savings because the large resin column uses
only a fraction of its capacity per batch.
To continue the high productivity puriﬁcation train, membrane col-
umns are also used for polishing. Fig. 3 shows Natrix's HD-Sb followed
byHD-Q, each having 6 s residence times aswell. The HD-Sbmembrane
requires only 14 cycles (total 3.3 h) per day to process the eluate from
the Protein A afﬁnity membrane. The high binding capacity of HD-Q
can process the HD-Sb puriﬁed product with only a single cycle in FT
mode for ﬁnal impurity reduction. Over the course of 10 days the
media life of these membranes is expended to process the entire batch
and capacity is not wasted to enable the fast ﬂowrates. These small
membrane columns (relative to resin columns), allow large quantities
of mAb to be processed in a small footprint facility.3. High Productivity, Single-use Membranes: Lab Scale Data Proof
of Concept
3.1. Materials and Methods
A new Protein A membrane formulation is being investigated at
Natrix Separations. The newmembrane is composed of a base formula-
tion that can be coupled in a secondary reaction to an afﬁnity ligand. The
ligand chosen for these studies is a base-stable Protein A sourced from a
known vendor.
The Protein A afﬁnity membrane experiments were run on Natrix
prototype membranes using four clariﬁed innovator and biosimilar an-
tibodies (mAb1, mAb2, mAb3, andmAb4) from Chinese Hamster Ovary
(CHO) cell culture. MAb1 and mAb3 were Human IgG1 antibodies with
molecular weight 144,190 Da and pI 8.25. MAb4was Human IgG1 anti-
body with molecular weight 145,531 Da and pI 8.45 andmAb2 was ob-
tained in conﬁdence from a biopharmaceutical company for membrane
studies. Prior to loading on the membranes, mAb1 andmAb2were pre-
treated with Millipore X0HC depth ﬁltration, whereas mAb3 and mAb4
were ﬁlteredwith 0.2 μmbottle top ﬁlters. Further information on buff-
er systems and puriﬁcation devices are detailed below, along with the
testing results. Cleaning treatment for the Protein A membranefollowing elution is 0.1 M acetic acid strip and 0.1 M sodium hydroxide
cleaning in place (CIP).
Protein A membrane lab scale experiments for evaluation of HCP
clearance for various mAbs and buffer conditions were performed
with 1 layer of membrane assembled in a 25 mm diameter stainless
steel housing (MV=0.12mL). The reference resin puriﬁcation platform
process included Amsphere™ Protein A column (ID 50 mm, bed height
20.5 cm, bed volume 403mL) followedby CEX puriﬁcation using POROS
XS column (ID 50mm, bed height 23.5 cm, bed volume 461mL) follow-
ed by AEX puriﬁcation using HiTrap™ QFF column (5 mL bed volume).
For the experimental membrane platform process, Protein A puriﬁca-
tionwas done using 2 layers of membrane stacked in a 47mmdiameter
test cell (MV = 0.8 mL) followed by CEX puriﬁcation using Natrix
HD-Sb Recon (MV=0.87mL) followedbyAEXpuriﬁcation usingNatrix
HD-Qmembrane (MV= 0.04 mL). All experiments were performed on
a GE Healthcare AKTA Puriﬁer.
3.2. Results
3.2.1. Membrane HCP Clearance Equal to Resins for Various mAbs and
Loading Conditions
In this study, SU Protein A membrane and Protein A resin
(Amsphere™ Protein A column, ID 5 mm, bed height 50 mm, bed vol-
ume 1.0 mL) were tested at laboratory scale with four different mAbs
to compare the performance of the different media (Table 1) and assess
platformability of the technology. Based on the data in Table 1, the level
of eluate HCP from the Protein Amembrane compared verywell or even
better than the Protein A resin, even with a wide HCP feed complexity,
from N25,000 ppm to N1,400,000 ppm (as determined by the Cygnus
III HCP ELISA kit). The high ﬂow rate of membrane columns (6 s resi-
dence time) allows puriﬁcation of similar loads in only a fraction of
the time compared to resin columns (4 min residence time).
The Protein A membrane was further tested with three different
buffer systems (Table 2) using mAb2, mAb3, and mAb4 to compare
HCP reduction performance under different conditions (Table 3). Differ-
ent mAb species can have varying characteristics and therefore HCP
reduction and elution efﬁciency can be improved by adjusting the buffer
strength, salt concentration, and pH as shown in Table 3. The high
ﬂowrate used with membrane columns allows for a fast elution step;
therefore very low pH (pH 3.0) can be used to quickly elute the column
Table 1
Comparison of HCP reduction using Protein A membrane and Protein A resin for four different mAbs. (* pretreated feed). Equilibration/wash 1 buffer: 1× PBS, pH 7.4. Wash 2 buffer: 1×
PBS + 1 M NaCl, pH 7.0. Elution buffer: 100 mM glycine, pH 3.0.
HD-A membrane Protein A resin column
Feed HCP (ppm) Load (mg/mL) Eluate HCP (ppm) Load (mg/mL) Eluate HCP (ppm)
mAb 1* 25,600 30 102 25 203
mAb 2* 89,667 30 307 25 247
mAb 3 319,649 25 527 25 2404
mAb 4 1,417,391 30 1171 25 1123
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rity clearance for different mAbs and matrices across multiple buffer
systems. In summary, the combined data from Tables 1 & 3, reveal the
Protein A membrane can support a wide range of mAbs, complex feed
impurities, and an array of buffer conditions with great HCP reduction
to offer a ﬂexible capture option that can adapt to varying feed and pro-
cess conditions.
3.2.2. Fully Single-use Downstream Process
The Protein A membrane improves mAb capture, and similar ad-
vancements have been reported for membrane columns used in polish
applications [58–61]. A lab scale process comparison between a fully
SUmembrane column platform and a traditional resin column platform
was performed using mAb3 to demonstrate the advantages of mem-
brane columns (Table 4). Three chromatography steps for typical mAb
puriﬁcation (Protein A, cation exchange, and anion exchange) were
studied at lab scale for both media. The membrane process showed
comparable HCP clearance for the cation exchange and anion exchange
steps and signiﬁcantly better clearance for the Protein A step (see
Table 4). The yields were similar for both processes, however themem-
brane columns were able to maintain equal or better HCP reduction &
yieldwith faster ﬂow rates and higher binding capacities. This translates
to amuchhigher productivity per volumeofmedia, resulting in a higher
throughput from themembrane processwith similar purity to the tradi-
tional resin column process.
3.2.3. Two Flow Through Steps to Optimize Downstream Throughput
The productivity of the polish processes discussed above can be
further increased by using the cation exchange membrane (HD-Sb)
column in FT mode instead of B&E mode (Table 5). In FT mode, the
mAb throughput capacity is 300 g/L with very good HCP reduction,
therefore increasing the amount of feed that can be processed in one
cycle. Table 5 shows examples of 2 different processes using HD-Sb in
FT mode followed by HD-Q in FT. Different Protein A puriﬁed mAb
feeds are used, with the feed for process 1 having high aggregate levels
and the feed for process 2 having greater HCP concentration. For both
processes 2 coupons of the corresponding membrane chemistry were
layered in a 25 mm diameter test cell. Buffer compositions are listed in
Table 6. The HD-Sb chemistry, with comparable performance at pH 5.5
and pH 7.5 in the FT mode (Table 5), demonstrates the robustness of
Natrix HD membranes. One notable performance advantage of the
HD-Sb membrane is the ability to reduce high aggregate levels in the
ﬂow through mode (Table 4) as well as B&E mode (data not shown).
Further, at pH 7.5, the FT conditions are the same for the HD-Sb and
HD-Q steps, creating the strategic option of a directly coupled tandem
polish process, which eliminates the need for buffer adjustmentTable 2
Equilibration, wash 1, wash 2, and elution buffers for 3 different buffer systems used to evalua
Equilibration and wash 1 buffer Wash 2 buffer
Buffer System 1 1× PBS, pH 7.4 1× PBS + 1 M NaCl, pH 7.0
Buffer System 2 20 mM sodium phosphate +150 mM NaCl,
pH 7.6
20 mM sodium phosphate +
Buffer System 3 20 mM Bis-Tris + 20 mM NaCl, pH 7.6 20 mM Bis-Tris + 1 M NaCl,between unit operations. Therefore, FT mode at pH 7.5 simpliﬁes the
process and reduces processing time and expense. Overall, the demon-
strated process performance of the HD-Sb and HD-Qmembranes allow
a wide range of process operations that can signiﬁcantly increase pro-
cess productivity while maintaining consistent impurity reduction and
good yield.
4. Impact of Single-use Strategy on Manufacturing Cost of Goods
Integrating innovative tools for both upstream and downstream
processing, using a holistic approach for the process and facility, pro-
vides an opportunity for complementary technologies to create syner-
gistic manufacturing strategies [62]. The shift in biopharmaceutical
manufacturing towards more ﬂexible, small footprint facilities requires
signiﬁcant changes tomany traditional processes.Many of the legacy fa-
cilities are often operating at partial capacity with outdated processes,
sometimes using equipment with dated engineering designs and/or
limited ﬂexibility. These facilities will have trouble competing with
biosimilars as well as keeping upwith new FDA (Food and Drug Admin-
istration) and EMA (EuropeanMedicines Agency) regulationsdue to the
high capital expenses, operational costs and regulatory burden [63,64].
On the other hand, SU systems are increasing in popularity, as a sur-
vey of biopharmaceuticalmanufacturers' reports, for various reasons in-
cluding reduced capital investment, decreased risk of product cross-
contamination, reduced start-up time, and eliminating cleaning
requirements [65]. Simulation and economic modeling software used
in the biopharmaceutical ﬁeld, such as Biosolve Process (Biopharm
Services) or SuperPro Designer (Intelligen) [66], are able to evaluate
differentmanufacturing scenarios to determine the impact of SU strate-
gies on process economics. An extensive review on the economics of
mAb manufacturing is hindered by the lack of peer reviewed articles
because many manufacturers do not share this sensitive information
except at conferences. This section summarizes data from modeling
software and existing facilities that has been presented at conferences
or published in peer reviewed journals.
To enable more affordable, higher throughput processing, existing
facilities can be retroﬁtted to incorporate advanced SU technologies.
With logistics, staff, and capital investment already in place as well as
reduced regulatory obstacles, established plants can smoothly transi-
tion to more economical processing. Biosolve analysis shows that oper-
ating costs per gramofmAb for a SU facility compared to a stainless steel
facility are 22% lower and this is primarily due to less labor, utilities,
maintenance, and waste [67]. In a case study presented at Cambridge
Healthtech Institute's PepTalk conference, annual savings of $250,000
in WFI (water for injection) generation costs and $60,000 in labor
time for set-up and cleaning stainless steel tanks were realized in ate HCP reduction for three mAb feeds.
Elution buffer
20 mM sodium acetate + 50 mM NaCl, pH 3.5
1 M NaCl, pH 7.0 100 mM glycine, pH 3.0
pH 7.0 20 mM Bis-Tris + 20 mM NaCl, pH 3.5 (acetic acid for pH adjustment)
Table 3
HCP reduction using Protein A membrane with different buffers and mAbs.
mAb 2 mAb 3 mAb 4
Feed HCP (ppm) 89,667 285,948 1,417,391
Buffer 1 eluate HCP (ppm) 307 527 1171
Buffer 2 eluate HCP (ppm) 382 710 1782
Buffer 3 eluate HCP (ppm) 2597 294 3098
Table 5
Evaluation of HCP and aggregate clearance for two processes both employing dual ﬂow
though polishing steps.
Process 1 Process 2
Feed HCP 247 ppm 1123 ppm
Aggregates 10.35% 1.91%
HD-Sb membrane column (FT mode) pH 5.5 7.5
Load 300 g/L 300 g/L
Yield 93% 88%
FT HCP 47 ppm 162 ppm
FT aggregate 0.49% 0.75%
HD-Q membrane column (FT mode) pH 7.5 7.5
Yield 93% 96%
FT HCP 3 ppm 26 ppm
FT aggregate 0.42% 0.74%
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containers and buffer hold bags [68]. When looking at DSP improve-
ments, chromatography resins make up a large portion of the costs so
changing a polishing step from resin chromatography to a SU mem-
brane column can signiﬁcantly reduce expenses, as demonstrated by a
Biosolve Process model that evaluates commercial mAb production
[69]. In this study of 1000 L and 5000 L scales and various mAb titres,
the unit operation cost is 19% to 33% lower for the membrane process
and buffer volume is decreased by up to 55% [69].
Instead of retroﬁtting an existing facility, new-build, state-of-the-art
SU facilities offer the same advantages and more without space con-
straints, non-optimized layouts, difﬁcult installations, and scheduling
constraints [70]. While an initial capital investment is still required,
this cost is much lower compared to building a multi-use (MU) facility
because many stainless steel skids and their associated hardware are
eliminated, equipment is smaller, and the building is smaller. In a
whitepaper published by Biopharm Services Limited, modeling soft-
ware shows that building a large-scale mAb process with thirty 2000 L
disposable bioreactors has a total capital investment of $250 M which
is a signiﬁcant reduction from the $352 M capital investment required
for a stainless steel facility with the same capacity [71]. In another
case study that compares the costs for a SU versus MU 2 × 1000 L new
facility, the SU facility saves €11 M annually in capital investment and
only costs €1 M more in operating costs [72,68]. This model shows
that signiﬁcant CapEx reductions result from lower engineering costs
(decreased by 83%) and instrumentation costs (decreased by 37%) and
the increased running cost was inﬂuenced mainly by a higher consum-
ables cost (increased by 51%) [72].
In addition to converting facilities to SU operations, the clean room
environment can be collapsed to encompass individual units which
are connected by SU tubing sets as in the FlexFactory concept developed
by Xcellerex [73]. This innovative design reduces the amount of space
required as well as protects the product from operator contamination.
Information shared at the International Society for Pharmaceutical Engi-
neering (ISPE) Strasbourg conference demonstrates that when compar-
ing 2000 L mAb production in a FlexFactory facility design versus
traditional infrastructure, the space required is reduced by 45%, water
usage is reduced by 87%, and capital cost goes down by 67% [74].Table 4
Comparison of resin and membrane mAb puriﬁcation platforms. Protein A Buffers: Equil-
ibration/wash 1 20mM sodiumphosphate+150mMNaCl pH7.6, wash 2 20mM sodium
phosphate pH 7.0, elution 100 mM glycine pH 3.0. CEX buffers: equilibration/wash 1 50
mM sodium acetate + NaCl pH 4.5, 15 mS/cm, wash 2 20 mM phosphate pH 6.5, Elution
20 mM phosphate + NaCl pH 6.5, 11.7 mS/cm AEX buffers: equilibration/wash 1 25 mM
Tris pH 7.5.
Puriﬁcation step Resin process
4 min residence time
Membrane process
6 s residence time
Protein A B&E load 25 g/L 40 g/L
B&E yield 95% 95%
Elution HCP 2476 ppm 294 ppm
CEX B&E load 50 g/L 55 g/L
B&E yield 80% 85%
Elution HCP 77 ppm 21 ppm
AEX FT load 250 g/L 20,000 g/L
FT yield 99% 99%
FT HCP 7 ppm 9 ppmCombined, these improvements cause a 32% reduction in the CoG to
$104.8 per gram of mAb [74]. The ﬂexible facilities of the future using
self-contained modules are also an attractive option for retroﬁtting or
new build facilities because the modules can be built offsite and then
installed in unclassiﬁed spaces. Entire processes can be designed in a
modular manner which allows fast replication of processes so they
can be installed anywhere in the world, as well as easy scale up by
just increasing the number of modules [75]. Models for this SU strategy
support the same order of cost improvements that was seen with the
Xcellerex FlexFactories for an expected capital cost of $25 M for a
new-build plant and CoG of mAb in the range of $85/g.
SU process analytical technology (PAT), such as disposable real
time monitoring systems, are also gaining popularity. Many bio-
manufacturers are adopting real-time SUmonitoring of key parameters
such as temperature, pH, dissolved oxygen (DO), and biomass. Beneﬁts
of disposable monitoring technologies include lack of sterilization re-
quirements, lowered risk of contamination, reduced operator exposure
to biohazardous substances, and conﬁrmation of real time process con-
ditions. Examples of disposable sensors include the SU, pre-calibrated
SciPress, SciCon and SciTemp sensors offered by SciLog Bioprocessing
Systems for in-line pressure, conductivity and temperaturemonitoring.
Suppliers also offer SU bioprocessing devices ﬁtted with disposable
sensors. Sartorius Stedim Biotech, for instance, provides the LevMixer®,
a magnetic mixer for volumes between 50 L to 1000 L with pre-
assembled SU probes for inline pH and temperaturemonitoring. Typical
applications of the LevMixer include buffer,media and feed preparation,
dilutions and pH adjustments, low pH viral inactivation, and product re-
formulation. Sartorius Stedim Biotech also offers the Flexsafe bioreac-
tors with welded BioPAT ViaMass sensor discs. The SU BioPAT ViaMass
sensor, developed by ABER Instruments, detects cell density level in
cell cultures through RF impedance spectroscopy.
SU bioprocessing analytical tools are not discussed in depth here
since this topic is out of the scope of this article. Readers are encouraged
to read (A Biopharmaceutical Industry Perspective on Single-Use Sen-
sors for Biological Process Applications, 2015) for a detailed review.
Although SU technologies bring several key advantages, there are a
few important limitations that cannot be overlooked.
First of all, SU tools are often manufactured from plastic derivatives.
There have been concerns raised regarding the effect of extractable and
leachable compounds, such as antioxidants, plasticisers, and curing
agents, from these plastic disposable technologies on the quality of the
ﬁnal product. For example, an extensive study by Amgen reports that
bis(2,4-di-tert-butylphenyl)phosphate (bDtBPP), a cytotoxic com-
pound, leaches from certain SU bags and impedes cell growth under
many cell culture conditions [76]. The Bio-Process Systems Alliance
(BPSA) has issued a comprehensive report outlining recommendations
for extractables and leachables testing from SU equipment [77]. On top
of the validation concern regarding leachable and extractable materials,
the use of plastic SU products also triggers the debate over their poten-
tial environmental impact.
Table 6
Equilibration and elution buffers HD-Sb and HD-Q membranes in 2 ﬂow through processes.
Membrane Buffer type Process 1 Process 2
HD-Sb Equilibration 50 mM sodium acetate + NaCl, pH 5.5, 10 mS/cm 20 mM sodium phosphate + NaCl, pH 7.5, 2 mS/cm
Elution 25 mM Tris + 1 M NaCl, pH 8.1 25 mM Tris + 1 M NaCl, pH 8.1
HD-Q Equilibration 25 mM Tris + NaCl, pH 7.5, 5 mS/cm 20 mM sodium phosphate + NaCl, pH 7.5, 2 mS/cm
Elution 25 mM Tris + 1 M NaCl, pH 8.1 25 mM Tris + 1 M NaCl, pH 8.1
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creasing concern about the adverse environmental effects from the
regular, large-volume disposal of plastic waste. Some suppliers have
assessed the possibility of recycling but concluded that the likelihood
is very limited due to mixed plastic content and possible requirement
of pre-treating biohazardous materials; so traditional methods of
disposing SU plastics through landﬁll and incineration will remain as
the standard [78]. While plastic waste management is a drawback for
SU technologies, several studies have shown that the environmental
beneﬁt of using SU technology due to reduced consumption of energy,
water, and cleaning agents compared to multi-use stainless steel facili-
ties outweighs the disadvantage and can signiﬁcantly reduce the overall
carbon footprint [79,78].
Consistency and availability of SUmaterials is another issue that can
directly affect the supply of SU products. Biopharmaceutical manufac-
turers expect availability of manufacturing materials with consistent
quality for the duration of the manufacturing campaign. Often, the
samematerial is required for future manufacturing campaigns to main-
tain consistency and prevent time-to-market delays due to validation
and quality assurance conﬂicts. In order to avoid such problems, sup-
pliers generally maintain a backup supply of materials, and support
end-users throughout the product's life-cycle. These issues with SU
technologies cannot be overlooked. Yet, the advantages of SU process-
ing such as cost efﬁciency and ﬂexibility outweigh these potential but
preventable problems. Moreover, new high productivity technologies
combined in a SU environment are able to provide further improve-
ments to mAb manufacturing. Incorporating high throughput units
into one section of a process pipeline can impact other areas such as
eliminating the need for extra steps, or allowing downsizing of other
unit operations. Not only is production cheaper and less complicated, fa-
cility construction and process validation time are signiﬁcantly short-
ened. For example, using SU membrane columns instead of MU resin
columns in commercial manufacturing eliminates the need for cycling
performance studies as well as resin storage and cleaning studies [54].
Disposable technologies were once seen as excellent for multi-
product, small volume facilities, but facing technical challenges or limits
to their economic advantage at large scales (multi-ton per year), as seen
in the case study discussed above (maximum size for SU bioreactors is
2000 L, pre-packed resin columns are limited to 45 cm and recently
60 cm inner diameter) [80]. However, next generation ﬂexible facilities
such as the one described in this paper will not suffer from these size
constraints since they are based on small batch sizes run multiple
times in multiple locations.
Disposable technologies support the shift in biopharmaceutical
manufacturing to smaller, ﬂexible facilities for 500 kg or less annual
market indications. Although there are still areas for improvement to re-
duce the CoG for SU manufacturing of blockbuster therapeutics, truly
ﬂexible facilities have the potential to be a viable alternative even in
the multi-ton market indications.
5. Summary and Outlooks
With the growing competition from biosimilars and the shift to-
wards smaller drug paradigms, companies are seeking cost efﬁcient
strategies for biotherapeutics manufacturing. The use of innovative
technologies enables the optimization of mAb manufacturing in areas
such as cost, throughput, and ﬂexibility. Right-sizing unit operationsby using improved perfusion bioreactors, depth ﬁltration, and modern
chromatographic strategies allow full use of each process operation's
capacity as well as downsizing of equipment and related infrastructure.
In this article, an in-depth look at platformable chromatography mem-
brane columns for Protein A capture as well as ion exchange polishing
demonstrates equal or better performance than traditional resin col-
umnswithmuch higher productivity; a result of high loading capacities
and residence times of only 6 s. A conceptual process integrating state-
of-the-art perfusion reactors and these SU membrane columns in a
small footprint, modular facility can promote much simpler and faster
mAb development and production.
Replacing traditional facilities, or ﬁrst generation ﬂexible facilities
where disposable technologies are implemented in the traditional par-
adigm, with a truly ﬂexible concept design allows for easy and rapid
scale up by increasing the number of cost-efﬁcient production units. In-
dustrial production at lab scale no longer requires technical and regula-
tory scale-up since these production units can be incorporated into
modular clean rooms. This simpliﬁes the replication (cloning) of the
process such that manufacturing facilities can be installed anywhere
in the world in only a few months (in-market/for-market strategy)
with no need to redevelop and characterize the process at larger scale.
Truly ﬂexible facilities will experience minimum expenses during clini-
cal phases and grow with market demand, hence minimizing risks
while optimizing time to market and global distribution without the
challenges of complex worldwide distribution logistics.
These changes have begun to be implemented in mAb manufactur-
ing but innovation does not have to stop here. Many areas of biologics
production, such as vaccine manufacturing where some current facili-
ties are more than 40–50 years old and use outdated, non-optimized
technology [35], can beneﬁt from the cost reductions associatedwith in-
tegrating emerging technologies. Despite the current proofs of concept
and successful introduction of new techniques in mAb processes,
there may be unforeseen challenges when extending ﬂexible
manufacturing strategies to other biologics. For example, perfusion bio-
reactors may not be able to deliver expected throughputs, challenging
feeds may require larger ﬁltration areas [81], and/or new chromatogra-
phy media might not meet productivity targets; all of which would in-
crease the CoG and facility footprint. Further development of SU,
ﬂexible technologies may be needed if expenses become too high or
integration and automation cannot be realized.
A ﬁnal step to high throughput biopharmaceutical production is im-
plementation of state-of-the-art PAT for continuousmonitoring and ad-
justment to ensure speciﬁcations are met. Small production skids,
disposable units, variable raw materials, and lack of real-time online
measurement devices are challenges for PAT integration, but new, so-
phisticated instruments show promising improvements [82]. Product
attribute control is now possible within the bioreactor, for example
with MAST (Modular Automated Sampling Technology), and advances
in Raman spectroscopy, at-line surface plasmon resonance (SPR), SU
sensors, chemometricmethods, and ultra high performance liquid chro-
matography (UPLC) at linemonitoring are helpingmanufacturers over-
come hurdles in DSP PAT integration [82–88].
While there are technologies available for optimizing biologics
manufacturing, the industry is slow to move away from the traditional
processes that have been proven to work even though they are becom-
ing outdated. It will become necessary for companies to adapt to SU and
continuous processing so they can stay competitive in global markets
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is also encouraged by the FDA because it reduces manual handling of
products, promotes better process control, and is aligned with their
quality by design (QbD) initiatives [89–91]. It is postulated that when
combined in a holistic, SU based process and facility strategy, the tech-
nology advancements described here will aid in reduction of drug sub-
stance manufacturing costs. Furthermore, it will enable a production
paradigm that is suitable for local manufacturing needs in developing
countries,meeting drugmanufacturing requirements and supplying pa-
tients with lifesaving medicines.
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